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Context: Estrogen resistance due to mutations in the estrogen receptor a gene (ESR1) has been
described in men and women and is characterized by osteoporosis, delayed bone age and con-
tinuous growth in adulthood, and delayed puberty and multiple ovarian cysts in women. Although
mutations in the estrogen receptor b gene ESR2 were found in 46, XY patients with differences of
sex development, no genetic variants of ESR2 were linked to gonadal defects in women.
Settings and Patient: Here we describe a 16-year-old female patient who came to our tertiary care
hospital with complete lack of estrogen action, as demonstrated by absent breast development,
primary amenorrhea, and osteoporosis, resembling patients with ESR1 mutation. However, her
gonads were clearly abnormal (streak), a finding not observed in ESR1-deficient patients.
Design: To gain insights into the molecular consequences of the ESR2 defect, whole exome se-
quencing and extensive functional transactivation studies in ovarian, bone, and breast cells were
conducted, with or without the natural activator of estrogen receptors, 17b-estradiol.
Results: We identified a loss-of-function heterozygous mutation of a highly conserved residue in
ESR2 that disrupts estradiol-dependent signaling and has a dominant negative effect, most likely
due to failure to interact with its coactivator, nuclear coactivator 1.
Conclusions: This is a report of a loss-of-function mutation in the estrogen receptor b in a young
woman with complete ovarian failure, suggesting that ESR2 is necessary for human ovarian
determination and/or maintenance and that ESR1 is not sufficient to sustain ovarian function
in humans. (J Clin Endocrinol Metab 103: 3748–3756, 2018)
Estrogens control development and cell differentiationand in adult organisms maintenance of homeostasis.
They do so by binding and activating their nuclear
receptors, estrogen receptor a (ESR1) and b (ESR2).
These receptors bind the same ligands (estradiol and
estron) with similar affinity and are almost ubiquitously
expressed within the body, so that the tissue distribution
and ratio between the two receptors determine the sen-
sitivity and type of reactions of the target tissue to the
common ligand. The available data in mice suggest that
ESR2 is a dominant-negative regulator of ESR1-
dependent transcription in a sort of yin-yang alliance
between the two ESRs (1, 2). Esr1 knockout mice of both
sexes are infertile, and the XX animals had hypoplastic
uteri and multicystic ovaries. Heine et al. (1) found that
male and female Esr1 knockout mice had hyperplasia
and hypertrophy of adipocytes, insulin resistance, and
glucose intolerance.
In patients, loss-of-function mutations in ESR1 cause
estrogen resistance characterized by osteoporosis, delayed
*These authors contributed equally to this study.
Abbreviations: DSD, differences of sex development; E2, 17b-estradiol; ESR, estrogen
receptor; ESR1, estrogen receptor a; ESR2, estrogen receptor b; NCoA1, nuclear
coactivator 1; WES, whole exome sequencing; WT, wild-type.
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bone age and continuous growth in adulthood, high estrogen
blood levels in both sexes (3–5), delayed puberty with no
breast development, and infantile uteri and primary amen-
orrhea and multiple ovarian cysts in women (4, 5). In ad-
dition, the first male patient displayed insulin resistance and
glucose intolerance (3), recapitulating themurine phenotype.
Several animal models of Esr2 deficiency have been
created, resulting in various phenotypes (6–8). The first
Esr2-deficient mouse model developed normally and was
indistinguishable from littermates, had no obvious re-
productive phenotype, but had fewer and smaller litters
than wild-type (WT) mice; these findings suggest that
Esr2 is essential for normal ovulation efficiency but is not
essential for female or male sexual differentiation, fer-
tility, or lactation in mice (9). However, the knockout in
this model was not complete because alternative tran-
scripts were still processed. Anothermousemodel ofEsr2
knockout with no expression of Esr2 showed infertility in
both male and female animals, without sex reversal (10).
In patients, an association between variants of the (CA)n
polymorphism and risk for hypospadias was reported
(11).More recently, monoallelic and biallelic inactivating
mutation in ESR2 has been reported in patients with
syndromic and nonsyndromic 46, XY differences of sex
development (DSD) (10). In addition, a girl with primary
amenorrhea and ESR2 mutation without ovarian dys-
genesis was reported by using a candidate single-gene
approach that does not exclude the contribution of
variants in other genes to the phenotype (12). Here we
describe a young woman with a point mutation in ESR2
identified via whole exome sequencing (WES) presenting
with streak gonads, absent puberty, no breast develop-
ment, infantile uterus, osteoporosis, but closed epiphysis.
Case Report
The patient presented in our clinic at 16.5 years of age
with absent breast development, fully developed pubic
hair, and primary amenorrhea. She was born in East
Africa, grew up in an orphanage, and came to Switzer-
land at age 15.5 years. She showed a eunuchoid habitus.
Her height was 150 cm, weight was 48.1 kg, sitting
height was 76.4 cm (24 SD), and ratio of sitting height to
subischial leg length was 22.2 SD. Blood pressure and
heart frequency were within normal limits. She showed
no signs of hyperandrogenism, such as acne or hirsutism.
Gynecologic examination revealed hypoplastic labia
majora, a nonestrogenized infantile vulva with signs of
sexual activity, and otherwise normal anatomy.
Bone age was 16 years according to Greulich and Pyle
criteria. Abdominal ultrasonography revealed a small infantile
uterus. No ovaries could be detected. Dual-energy x-ray
absorptiometry showed severe osteoporosis (Z-values:
total body, 24 SD; lumbar, L1 to L4, 24.2; right femur,
22.2; left femur, 22.2). On initial laboratory examination,
serum E2 estradiol level was 59 pmol/L (normal range, 75 to
392 pmol/L), LHwas 8.7 U/L (normal range, 1.1 to 3.8 U/L),
and FSH was 24.4 U/L (normal range, 1.4 to 4.2 U/L). Her
karyotype was 46,XX. Anti–Mu¨llerian hormone was very
low at 0.1 pmol/L (normal, .8 pmol/L). Serum androgen
concentrations were within normal range [testosterone,
0.9 nmol/L (normal range, 0.2 to 1.8 nmol/L); andros-
tenedione, 2.6 nmol/L (normal range, 1.4 to 7.9 nmol/L);
and dehydroepiandrosterone sulfate, 3.5 mmol/L (normal
range, 2.2 to 10 mmol/L)]. Antiovarian autoantibodies
were negative. Thyroid function, prolactin, and hemato-
logic parameters were all within normal limits. Total
cholesterol was 5.4 mmol/L (normal, ,5 mmol/L), low-
density lipoprotein cholesterol was 3.8 mmol/L (nor-
mal,,3mmol/L), high-density lipoprotein cholesterol was
1.2 mmol/L (normal, .1 mmol/L), and triglycerides were
0.8 mmol/L (normal, ,2.0 mmol/L). Homeostasis model
assessment index was 0.7(normal, ,3.5 nmol/L) and
25-hydroxy vitamin D3 was 43.3 nmol/L (normal,
.50 nmol/L) (Supplemental Table 1).
She was started on transdermal estrogen therapy
with an initial dose of 12.5 mg. She showed signs of
breast development around 3 weeks after initiation of
transdermal estradiol application. Estradiol dose was
sequentially increased and eventually switched after
6 months to a cyclic transdermal E2/progesterone prep-
aration. Menarche appeared after the first month of cyclic
hormone replacement, followed by regular menses. A
combination therapy with calcium and vitamin D was
introduced because of low bone density. The 2-year
follow-up under treatment with estrogen and calcium/
vitamin D3 showed a change of bone density (Z-values:
total body, 23.3 SD; lumbar L1 to L4, 23.3; right
femur, 21.8; left femur, 21.9), but the values are still
abnormal and require a long-term reevaluation.
Ultrasonography under estrogen replacement therapy
revealed stimulated endometrium and increased uterus
volume of 8 mL. Ovaries could now be identified but
appeared as streakswithout follicles (Supplemental Fig. 1).
Tables 1 and 2 summarize clinical and laboratory data and
compare them to those of the ESR1-deficient patients.
Informed written consent was obtained, and WES
analysis was performed.
Materials and Methods
WES
Genomic DNA samples from the patient were analyzed by
WES on a SureSelect Human All Exon V.6.0 capture kit
(Agilent Technologies, Santa Clara, CA) and a HiSeq 4000
Sequencer (Illumina, San Diego, CA). The reads were screened
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with FastQ Screen (Babraham Bioinformatics, Cambridge,
United Kingdom) for possible contamination, and a quality
control has been performed with FastQC (Babraham Bio-
informatics). Read alignment has been performed with
Bowtie 2 (Johns Hopkins University, Baltimore, MD) against a
human reference sequence (GRCh37.p13/hg19). GATK Hap-
lotypeCaller (Broad Institute, Cambridge, MA) was used for
calling single-nucleotide polymorphisms and indels, and the
aligned data were visualized with the Integrative Genomics
Viewer (Broad Institute). The filtering of candidate variants by
frequency and prediction of intolerance to loss of function was
analyzed by using the ExAC browser (Exome Aggregation
Consortium, Broad Institute).
ESR2-targeted mutational analysis
Genomic DNA was extracted from peripheral blood leuko-
cytes (Qiagen DNA blood and cell culture kit; Qiagen GmbH,
Hilden,Germany). All exons fromESR2 (RefSeqNG_011535.1),
including the intronic regions,were amplified and sequencedwith
ESR2-specific primers (Supplemental Table 2). Direct sequencing
of the polymerase chain reaction products was performed with
the use of the ABI Prism BigDye Terminator Cycle Sequencing
Ready Reaction Kit (Applied Biosystems, Life Technologies
Corp., Austin, TX) and analyzed with the use of the 3500 Series
Genetic Analyzer (Applied Biosystems, Carlsbad, CA).
Protein model and in silico mutagenesis of ESR2
The three-dimensional model of the ESR2-ligand binding
domain sequence (amino acids 261 to 500) was built by
referring to the crystal structure of ESR2 (3OLL) as a template
and by using the program YASARA (YASARA Biosciences
GmbH, Vienna, Austria). In silico mutagenesis was per-
formed to create the K314R mutation by using the muta-
genesis tool from PyMOL (Schro¨dinger, New York, NY). The
models were refined with a 1000ps molecular dynamics
simulation by using an Assisted Model Building with Energy
Refinement 2003 force field. Finally, both models were
checked with the programs ERRAT (University of California,
Los Angeles, Los Angeles, CA), RAMPAGE (University of
Cambridge, Cambridge, United Kingdom), and Verify3D
(13). The structures were depicted by using PyMOL
(Schro¨dinger).
Site-directed mutagenesis
The site-directed mutation of Lys314 to arginine was in-
troduced in a green fluorescent protein–tagged cDNA clone
ESR2 (NM_001437) from OriGene (OriGene Technologies,
Rockville, MD). The mutation was performed by using the
QuikChange Site-Directed Mutagenesis Kit (Agilent Technol-
ogies) according to the manufacturer’s instructions. The mu-
tagenic oligonucleotides used are shown in Supplemental
Table 3.
Thermocycler conditions for the single amino acid
mutation were as follows: 95°C for 2 minutes, 18 cycles of
95°C for 30 seconds, 55°C for 1 minute, followed by
68°C for 8 minutes, with a final extension at 68°C for 10
minutes. The resulting mutant plasmids were verified by
DNA sequencing.
Table 1. Clinical Comparison Between ESR1 and ESR2 Defects
Variable
ESR1
Patient 1a Patient 2b Patient 3c Patient 4c Patient 5c
Age of
presentation, y
28 15 25 21 18
Karyotype 46, XY 46, XX 46, XX 46, XX 46, XY
Gender identity Male Female Female Female Male
Clinical
presentation
Tall stature
Genu valgum
Long legs
Acanthosis nigricans
Male baldness
No breast development
Primary amenorrhea
Intermittent lower
abdominal pain
Facial acne
No breast development
Primary amenorrhea
Chest acne
No breast
development
Primary
amenorrhea
Cryptorchid right
testis,
left testis , 1 mL
Pubertal
development
(Tanner stages)
G5 P5 (testes 25 mL) B1 P4 B1 P5 B1 P5 G1 P2
BMI, kg/m2 30.5 16.6 26.3 22.9 23.7
BA, y 15 (at CA 28) 11-12 (at CA 15 5/12) 13 (at CA 19) 13 (at CA 21) 11 (at CA 18)
Abdominal
ultrasound
NA Small uterus
No endometrium
Large polycystic
ovaries
Small uterus
thin endometrium
Large polycystic ovaries
Large polycystic
ovaries
NA
Other features Insulin resistance/
glucose intolerance
Mild hypothyroidism
Osteoporosis Mild Mild NA NA NA
Effect of E2
replacement
No epiphyseal fusion No breast development NA NA NA
(Continued)
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Cell culture and transfection
The human female breast adenocarcinoma cell line MCF-7
and the osteosarcoma cell line U2-OS (female) were cultured in
DMEM and the human ovarian granulosa-like tumor cell line
(female), KGN in DMEM/ F-12 media (Sigma-Aldrich, St.
Louis, MO) supplemented with 10% newborn calf serum,
100 U/mL penicillin, and 100 mg/mL streptomycin. For tran-
sient transfection assays,MCF-7, U2-OS, and KGNwere plated
in six well plates and grown up to 60% to 70% confluence
before transfection with the use of Metafectene (Biontex
Laboratories, Mu¨nchen, Germany). Each well was transfected
with a total of 1 mg DNA for 48 hours, washed with PBS before
being lysed, and collected for assessment.
Transactivation assay
We contransfected 500 ng/well of the luciferase reporters
from the EREReporter Assay Kit (Qiagen GmbH) with the ESR
constructs by using Metafectene. Forty-eight hours later, cells
were lysed and luciferase assays were performed by using a
Dual-Luciferase® Reporter Assay System (Promega, Madison,
WI) on a single-tube luminometer LB9508 Lumat3 (Berthold
Technologies, Bad Wildbad, Germany) following the manu-
facturer’s protocol. Transfection of each construct was per-
formed in triplicate in each assay, and a total of three assays
were performed on 3 separate days. The results are expressed as
the mean 6 SEM of the independent experiments.
Ligand (E2) dose response
The cells were transfected as described for the luciferase
assay above with ESR2WT or ESR2mutant in duplicates. The
medium was replaced the next day with medium containing
10212, 10210, 1029, 1028, 1027, or 1026 mole E2. Again,
24 hours later, the cells were washed with 13 PBS before being
lysed and collected for assessment using the Dual-Luciferase®
Reporter Assay System as described above. Transfection of
each construct was performed in duplicates in each assay
and a total of three assays were performed on three separate
days. The results are the mean 6 SEM of independent
experiments.
Immunofluorescence
Cells grown on cover slips were transfected as described
above. Forty-eight hours later, the cells were fixed with 4%
formaldehyde (wt/vol) in 13 PBS for 15 minutes at room
temperature. Cover slips were mounted with Vectrashield
(Vector Laboratories, Inc., Burlingame, CA) containing 40,6-
diaminidino-2-phenylindole. Images were acquired by using a
Nikon eclipse NI-E microscope system.
Table 1. Clinical Comparison Between ESR1 and ESR2 Defects (Continued)
ESR2
Patient 6d Patient 7d Patient 8d Current Patient
15 12.5 24 16.5
46, XY 46,XY 46,XY 46, XX
Female Female Female Female
Female external genitalia Clitoromegaly, urogenital sinus Female external genitalia
Primary amenorrhea
Long legs
(SH/SILL ratio, 22.2 SD)
No breast development
(infantile nipples)
Hypoplastic labia majora
Primary amenorrhea
B1 P3 NA B1 P4 B1 P4
18 17.8 20.8 21.3
Delayed 11.5 (at CA 12.5) NA 15.5
Absence of gonads
Large cyst at the right adnexal
region containing
Wolffian remnants
No uterus No visible gonads
Infantile uterus
Small infantile uterus
No visible gonads
Anal atresia
Blepharophimosis, ptosis,
nystagmus, severe myopia,
dysmorphic features
No insulin resistance
NA NA NA Severe
B5 NA NA B5 P5; menarche; uterus 8 mL
Streak gonads, volume
0.5–1 mL without follicles
Abbreviations: BA, bone age; CA, chronological age; NA, not available; SH, standing height; SILL, subischial leg length.
aReference 3.
bReference 4.
cReference 5.
dReference 10.
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Western blot
Western blot analysis was performed according to standard
procedures using the monoclonal mouse anti–green fluorescent
protein antibody (Antiturbo GFP Monoclonal Antibody TA
150041, OriGeneTechnologies), diluted at 1:2000, as first
antibody and the anti-mouse antibody peroxidase (NIF825),
diluted at 1:5000, as secondary antibody. The antibody against
atubulin, GT 114 (GTX628802, GeneTex, Inc. Irvine, CA),
was used as control for amount and quality of the proteins.
Results
WES identified a heterozygous missense mutation—a tran-
sition from A to G—in the fifth coding exon of ESR2 (NM_
001040275.1:c.941A.G, on protein level: p.Lys314Arg)
that was confirmed by targeted Sanger sequencing
(Supplemental Fig. 2A). Of note, lysine 314 is an
evolutionary highly conserved residue (Supplemental
Fig. 2B).
Although DNA of parents is not available (the patient
is an orphan East African refugee), the mutation was not
found in ExAc database or in 300 controls, including 15
race-matched controls, and is predicted to be pathogenic
(Sorting Intolerant From Tolerant score, 0.01: deleterious;
Polymorphism Phenotyping score, 0.999: probably
damaging).
WES allowed us to examine variations in 85 genes
known to be implicated in 46,XY and 46,XX DSD (14)
as a filtering tool with the help of the Integrative Ge-
nomics Viewer (Supplemental Table 4). We discovered
multiple heterozygote and homozygote variants in ad-
ditional genes apart from ESR2. However, these variants
were very common polymorphisms found with a high
frequency in the general population (ExAC) (15) or were
predicted to be benign variants by Polymorphism Phe-
notyping and Sorting Intolerant From Tolerant.
We also did not find any pathogenic variant in other
genes known to be related to premature ovarian fail-
ure (Supplemental Table 5). To further expand the list
of possible targets, we identified factors linked to ESR
signaling, including ESR1, using Pathway Studio
software (Elsevier, New York, NY) and again found no
mutation predicted to be relevant for disease (Supple-
mental Fig. 3; Supplemental Table 6).
To gain more insights into the mechanism of disease,
we performed molecular modeling of the mutant ESR2.
The substitution of the highly conserved lysine with an
arginine at position 314 was predicted to impair the
interaction of the mutant ESR2 with nuclear coactivator
1 (NCoA1) (Fig. 1).
Transactivation studies of an estrogen-responsive
element–dependent luciferase reported gene were con-
ducted in three cell types, modeling three sites of es-
trogen action apparently affected in our patient: the
ovarian KGN, the breast MCF7, and the bone U2OS
Table 2. Comparison of Endocrine Profiles Between ESR1- and ESR2-Deficient Patients
Variable
ESR1 ESR2
Patient 1a Patient 2b Patient 3c Patient 4c Patient 5c Patient 6d Patient 7d Patient 8d Current Patient
Age of
presentation, y
28 15 25 21 18 15 12.5 24 16.5
Karyotype 46, XY 46, XX 46, XX 46, XX 46, XY 46, XY 46,XY 46,XY 46, XX
Gender identity Male Female Female Female Male Female Female Female Female
Estrone (E1) ↑↑ ↑↑↑ NA NA NA NA NA NA N
111 pmol/L (NV, 75–392)
Estradiol (E2) ↑↑ ↑↑↑ ↑↑↑ ↑↑↑ n Unknown
Likely ↓
Unknown
Likely ↓
Unknown
Likely ↓
↓
59 pmol/L (NV, 110–375)
LH ↑ N ↑ ↑ ↑↑ ↑ ↑ ↑ ↑
8.7 U/L (NV, 1.1–3.8)
FSH ↑↑ N-↑ ↑ ↑ ↑↑ ↑↑↑ N ↑↑ ↑↑
24.4 U/L (NV, 1.4–4.2)
Inhibin B NA N (for Tanner 1) ↑↑ NA NA ↓↓ NA NA ↓
,7 pg/mL (NV, 10–200)
AMH N N NA NA ↓↓ NA NA ↓↓
0.2 pmol/L (NV . 8)
Total testosterone N N-↑ ↑ ↑ ↓↓ ↓↓ NA NA N
0.9 nmol/l (NV, 0.2–1.8)
DXA 22 SD Z-value: 22.4 NA NA NA NA NA NA Z-value: 24.0
Osteocalcin ↑ ↑ NA NA NA ↑
47 mg/L (NV, 11–43)
Abbreviations: DXA, dual-energy x-ray absorptiometry; N, normal; NA, not available; NV, normal value; ↓ slightly decreased; ↓↓ mildly decreased; ↓↓↓
highly decreased; ↑ slightly increased; ↑↑ mildly increased; ↑↑↑ highly increased.
aReference 3.
bReference 4.
cReference 5.
dReference 10.
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cells. In KGN pregranulosa cells, the mutant ESR2
has a transactivation capacity similar to that of neg-
ative control (empty vector)—that is, it is unable to
drive the expression of the luciferase reporter gene and
has a significant dominant negative influence on its WT
counterpart (Fig. 2A), which is in agreement with the
heterozygote state. ESR1 was not tested in these cells
because ESR2 is the predominant estrogen receptor
in granulosa cells of the developing gonad (16–18).
The transcriptional activity of the mutant ESR2 was
not rescued by increasing quantities of the natural ligand
17b-estradiol (E2) (Fig. 2A), suggesting a complete loss
of function.
In MCF7 breast and U2OS bone cells, the mutant
ESR2 was completely inactive and had a dominant
negative effect on the otherwise very active WT ESR2
(Fig. 2B). Coexpression of ESR1 and ESR2 signifi-
cantly reduced ESR2-dep transactivation without al-
tering and increasing ESR1 activity in MCF7 and
U2OS bone cells, respectively (Fig. 2C), contradicting
the hypothesis that ESR2 modulates/decreases ESR1-
mediated gene transcription in mice (2). When chal-
lenged with E2, the mutant ESR2 in breast cells had a
much lower basal transactivation potential than the
WT receptor, but it showed a partial rescue at higher
E2 dose. In osteoblasts, the E2 dose response curve
showed a reduced transactivation capacity of the
mutant ESR2, which is partially rescued under higher
E2 dose.
Protein quantity, stability, and nuclear localization of
overexpressed mutant ESR2 in breast, bone, and granulosa
cells (MCF7, U2OS, and KGN cells, respectively) were
similar to those of to WT protein (Supplemental Fig. 4
and 5).
Discussion
Here we describe a 16-year-old adolescent who pre-
sented with complete lack of breast development, in-
fantile uterus, and primary amenorrhea as well as
severe osteoporosis, all suggestive of a defective es-
trogen action. Her phenotype resembled that of 46, XX
ESR1-deficient patients (3–5), with some notable dif-
ferences (Table 1): Her bone age was adult rather than
the delayed bone age and continuous growth of the
ESR1 patients, her androgens were normal, and her
estrogens were low (and not massively elevated as in
the ESR1-deficient cases). Her ovaries were not visible
at ultrasound, in contrast to the enlarged multicystic
ovaries of the ESR1 patients, and markers of gran-
ulosa cell health, such as Anti–Mu¨llerian hormone and
inhibin B, were unmeasurable, suggesting absence of
follicles/streak gonads. Furthermore, under exoge-
nous estrogens, the patient developed breast and uter-
ine maturation and (with the addition of progestin)
menstrual bleeding, in contrast to the ESR1-defective
cases.
Taking advantage of next-generation sequencing
approaches, we identified a point mutation in ESR2
leading to the exchange of an evolutionary highly
conserved lysine to an arginine, predicted to be del-
eterious. Although the patient’s parents were not
available for examination (the patient is an orphan East
African refugee), the mutation was not found in any of
the known single-nucleotide polymorphism databases
(although no extensive genetic database of sub-Saharan
population exists) or in 300 controls, including a small
number of race-matched individuals. The unbiased WES
approach did not show any other relevant variation
in gonadal development/DSD/premature ovarian in-
sufficiency genes or in genes linked to ESR signaling,
including ESR1. Molecular modeling of the mutated
Figure 1. Molecular modeling of WT and mutant ESR2.
Superimposition of WT-ESR2 (green) and ESR2-K314R (cyan)
protein models (ligand binding domain), shown as ribbon
diagrams. The residues of 314 are shown as stick models, the WT
residue in blue, and the mutant residue in red. The a helices
depicted in orange (light, WT; dark, mutant) are fragments of the
ESR cofactor NCOA1. The K314R mutation leads to a change in
the binding site of NCoA1. (A) Bound estrogen is depicted as
a stick model in pink. The NCoA1 binding site is compared
between WT (green) and mutant (cyan) models. (B) The WT
Lys314 potentially participates in the binding of the cofactor,
through polar contact (yellow dots) with the amino acids Leu699
and Gln701 of NCoA1. In the mutant model, the polar contact at
this amino acid positions is lost because of the mutant Arg314.
This in turn might lead to a diminished or lost interaction between
ESR2 and its cofactor NCoA1.
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ESR2 suggested that its interaction with the tran-
scriptional regulator NCoA1 might be impaired.
NCoA1 interacts with and enhances the transcriptional
activity of several nuclear receptors, including pro-
gesterone, androgen, estrogen, glucocorticoid, thyroid,
and retinoid X receptors. NCoA1 is recruited to DNA
promotion sites by ligand-activated nuclear receptors
(19, 20). NCoA1, in turn, acetylates histones, which
makes downstream DNA more accessible to transcrip-
tion factors. Hence, NCoA1 assists nuclear receptors in
the upregulation of DNA expression.
Although the mutation did not impair protein sta-
bility or nuclear localization, it did significantly impair
ESR2 signaling. To analyze the effects of mutation in
different estrogen-responsive tissues, we studied the ef-
fect on ESR-dependent signaling in ovarian, breast, and
bone cells.
In the ovary, ESR2 is the dominantly expressed ESR in
the granulosa cells of the small growing and preovulatory
follicles and ESR1 much less or not at all in various
species (16–18, 21), and in the human fetal ovary during
the ninth to the 15-16th gestational week, a time crucial
for gonadal development (E. Lecluze, personal commu-
nication). The description of 46, XY patients with DSD,
gonadal dysgenesis, and mutations in ESR2 (10) dem-
onstrated an unexpected role forESR2 in testis formation
Figure 2. Reduced estrogen receptor activity. Transactivation of an estrogen responsive element (ERE) upstream of the luciferase
construct revealed greatly reduced activity (measured as relative light units, RLU) by the mutated ESR2 (ESR2Mut) compared with WT
(ESR2WT),without rescue under treatment with increasing concentrations of the natural ligand E2 in (A) pregranulosa KGN cells, (B)
breast MCF cells, or osteoblast-like U2OS cells. In almost all cases, ESR2Mut had a dominant negative effect over the normal ESR2 and
ESR1 receptors (ESR2WT, ESR1WT). In (C) bone cells the combination of mutant ESR2 (ESR2Mut) with the normal ESR1 (ESR1WT) seemed to
increase the activity of the latter. The results are represented as mean 6 SD of three independent experiments. Significance was
calculated by using an unpaired t-test. ****P , 0.0001; ***P , 0.001; **P,0.01; *P,0.05. Abbreviation: EV, empty vector; water,
mock transfection.
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and suggested a possible function of ESRb in early go-
nadal development, which was not seen in the first mouse
model. More recently, another mouse model of Esr2
knockout with no expression of Esr2 showed infertility in
both male and female animals (10). In our case, the
mutated ESR2 completely lost its function in the pre-
granulosa cell system, showed a dominant negative effect
on the normal receptor (which may account for the
haploinsufficiency), and was not stimulated by exogenous
estradiol.
The effect of the ESR2 mutation on mammary and
uterine development is unclear because of the in-
adequate estrogen production by the failing ovaries.
The prompt response of breast and uterine tissue to
exogenous estrogens confirms that ESR1 is sufficient
and necessary to stimulate breast and endometrial
growth.
The explanation of the bone phenotype is more
challenging: Although the severe osteoporosis is com-
patible with estrogen deficiency (due to the gonadal
failure) and/or estrogen resistance (due to ESR2 muta-
tion), the epiphyseal closure in the absence of estrogen
production is difficult to account for. To further com-
plicate the issue, there are conflicting reports on the lo-
calization and function of ESR1 and ESR2 in growth
plate chondrocytes, with some studies identifying pre-
dominantly ESR1 (22) and others, ESR2 (23) or both
ESR1 and ESR2 (24), in the hypertrophic zone.
In our functional studies, the mutant ESR2 seemed to
increase the transactivation potential of ESR1 in bone,
perhaps via an increased availability of NCoA1, set free
by the mutant ESR2 that cannot efficiently recruit it. On
the other hand, in our expression studies, normal WT
ESR2 seemed to work in bone cells at very low con-
centration of E2 (0.1pmol), mirroring the estrogen levels
measured in our patient, and is not affected by mutant
ESR2: Bone maturation/epiphyseal closure in our patient
might have been stimulated by low levels of estrogen
derived by the peripheral conversion of adrenal androgen
precursors. On the other hand, given the very low es-
tradiol levels to be expected in this patient, a ligand-
independent ESR activation (25) might partly contribute
to these effects.
The 2-year follow up under estrogen (with calcium/
vitamin D) treatment showed a promising but much
less notable improvement of bone density parameters
(compared with breast and uterus), again suggesting a
more complex or slower influence of estrogens on bone
health/homeostasis.
The role of ESR2 in the regulation of the
hypothalamus/pituitary/gonadal axis is unclear. Al-
though adult GnRH neurons express ESR2 but not
ESR1 in all species studied, targeted deletion of ESR2
does not alter E2-mediated GnRH expression in these
neurons, suggesting that a direct action of estrogens
through ESR2 remains to be elucidated (26, 27). In our
patient, the elevated basal gonadotropins were due
to primary hypogonadism (lack of estrogen negative
feedback) and suggest that ESR2 is not necessary for
FSH/LH secretion, mirroring the findings in the 46,XY
DSD patients (10). Nevertheless, because FSH levels were
expected to be higher, a partial effect on the hypothalamus/
pituitary/gonadal axis and gonadotropins secretion can-
not be excluded.
Estrogens are involved in neurogenesis, and clinical as
well as experimental evidence supports their protective
effect against neurodegenerative diseases, such as Alz-
heimer and Parkinson disease (28–30). In Esr2-deficient
female mice, Krezel and coworkers (31) observed a be-
havior consistent with increased anxiety and concluded
that, particularly in females, there is an important role for
Esr2-mediated estrogen signaling in the processing of
emotional behavior. Furthermore, Rissman et al. (32)
showed that E2 affects learning and memory via Esr2 in
mice. In our illiterate patient, we did not observe any
neurologic deficit, but she seems to have a learning
disability. She has not yet learned to read. Her behavior
was quite inconspicuous. Thus, the role of ESR2 in
the central nervous system in humans still needs further
investigation.
The discovery of ESR2 by Gustafsson and co-
workers (33) opened the way to a deeper under-
standing of the complex and multiple actions of
estrogens, showing that it is not the ligand but the
relationship between the two receptors that determines
the variety of estrogen effects. Here we describe a
young woman in whom a loss-of-function mutation in
the ESRb led to early-onset complete ovarian in-
sufficiency, suggesting that ESR2 is necessary for early
human ovarian development and/or maintenance and
that ESR1 is not sufficient to support ovarian function
in women. It remains to be established whether es-
trogen resistance due to milder defects in ESR2 might
account for unexplained cases of premature ovarian
failure or infertility.
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